Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT00683592 Completed - Clinical trials for Major Depressive Disorder

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to evaluate genetic biomarkers of treatment response associated with vilazodone use in adult patients diagnosed with MDD by the DSM-IV-TR criteria.

NCT ID: NCT00672958 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Start date: April 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.

NCT ID: NCT00672620 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

Start date: April 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

NCT ID: NCT00668525 Completed - Clinical trials for Major Depressive Disorder

Escitalopram in Adult Patients With Major Depressive Disorder

Start date: April 2008
Phase: Phase 3
Study type: Interventional

This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.

NCT ID: NCT00644358 Completed - Clinical trials for Major Depressive Disorder

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Start date: December 31, 2007
Phase: Phase 3
Study type: Interventional

This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.

NCT ID: NCT00635219 Completed - Clinical trials for Major Depressive Disorder

Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder (MDD).

NCT ID: NCT00633399 Completed - Clinical trials for Major Depressive Disorder

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD). We are studying the drug's effectiveness in treating depression, as well as its safety when it is added to another drug. Hypothesis A: There will be a difference in the percentage of responders in the two treatment conditions during phase 2; response rates will be higher for the ziprasidone group.

NCT ID: NCT00621270 Completed - Anxiety Clinical Trials

Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.

NCT ID: NCT00619619 Completed - Depression Clinical Trials

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR in children and adolescents with major depressive disorder.

NCT ID: NCT00612807 Completed - Clinical trials for Major Depressive Disorder

Treatment of Mood and Marriage Study (TOMMS)

Start date: July 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The primary goal of this study is to develop and test a depression-specific marital therapy tailored for use with older adult populations.